Cargando…
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease
The accumulation of β-amyloid in the brain is an early event in Alzheimer’s disease. This study presents the first patient with Alzheimer’s disease who underwent positron emission tomography imaging with the amyloid tracer, Pittsburgh Compound B to visualize fibrillar β-amyloid in the brain. Here we...
Autores principales: | Kadir, Ahmadul, Marutle, Amelia, Gonzalez, Daniel, Schöll, Michael, Almkvist, Ove, Mousavi, Malahat, Mustafiz, Tamanna, Darreh-Shori, Taher, Nennesmo, Inger, Nordberg, Agneta |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3009843/ https://www.ncbi.nlm.nih.gov/pubmed/21149866 http://dx.doi.org/10.1093/brain/awq349 |
Ejemplares similares
-
CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
por: Karami, Azadeh, et al.
Publicado: (2019) -
Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography
por: Schöll, Michael, et al.
Publicado: (2015) -
Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
por: Saint-Aubert, Laure, et al.
Publicado: (2016) -
Re-Evaluation of Clinical Dementia Diagnoses with Pittsburgh Compound B Positron Emission Tomography
por: Degerman Gunnarsson, M., et al.
Publicado: (2013) -
Positron emission tomography
Publicado: (1995)